Golimumab Therapy in Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimuma...
Main Author: | Won Moon |
---|---|
Format: | Article |
Language: | English |
Published: |
Jin Publishing & Printing Co.
2016-02-01
|
Series: | The Korean Journal of Gastroenterology |
Subjects: | |
Online Access: | http://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2016.67.2.64 |
Similar Items
-
Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
by: M. Galván-Banqueri, et al.
Published: (2015-01-01) -
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
by: Pugliese D, et al.
Published: (2016-02-01) -
ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
by: E. V. Voronina, et al.
Published: (2018-12-01) -
BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01) -
Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab for refractory pouchitis after restorative proctocolectomy in patients with ulcerative colitis
by: Motoi Uchino, et al.
Published: (2017-10-01)